189 related articles for article (PubMed ID: 908006)
1. Factor XIII deficiency in BALB/c mice with plasmacytoma.
Eipe J; Yakulis V; Costea N
Cancer Res; 1977 Oct; 37(10):3551-5. PubMed ID: 908006
[TBL] [Abstract][Full Text] [Related]
2. Determination of factor XIII activity and of factor XIII inhibitors using an ammonium-sensitive electrode.
Hellstern P; Schilz K; von Blohn G; Wenzel E
Thromb Haemost; 1983 Aug; 50(2):563-6. PubMed ID: 6138878
[TBL] [Abstract][Full Text] [Related]
3. Imuran-induced regression of plasma cell tumor MOPC-315.
Schlossberg M; Hollander VP
Cancer Res; 1973 Aug; 33(8):1953-6. PubMed ID: 4720804
[No Abstract] [Full Text] [Related]
4. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
Adler A; Altbaum I
J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
[TBL] [Abstract][Full Text] [Related]
5. Effect of iron deficiency on transplantable murine plasmacytoma.
Benbassat J; Hershko C; Laskov R; Eliakim M
Nutr Cancer; 1981; 3(1):20-6. PubMed ID: 7346786
[TBL] [Abstract][Full Text] [Related]
6. [Behavior of the fibrin-stabilizing blood coagulation factor XIII in hemorrhages after tooth extractions].
Vogel C
Dtsch Zahnarztl Z; 1980 Jan; 35(1):137-8. PubMed ID: 6967809
[TBL] [Abstract][Full Text] [Related]
7. Human factor XIII: fibrin-stabilizing factor.
Lorand L; Losowsky MS; Miloszewski KJ
Prog Hemost Thromb; 1980; 5():245-90. PubMed ID: 7422874
[No Abstract] [Full Text] [Related]
8. Factor XIII-deficiency in the blood of venous leg ulcer patients.
Vanscheidt W; Hasler K; Wokalek H; Niedner R; Schöpf E
Acta Derm Venereol; 1991; 71(1):55-7. PubMed ID: 1676216
[TBL] [Abstract][Full Text] [Related]
9. [Proceedings: Determination of Factor XIII (fibrin-stabilizing factor) in plasma and blood platelets].
Ballerini G; Franceschini F; Guerra S; Meduri P; Scagliarini F
Quad Sclavo Diagn; 1973 Mar; 9(1):497-581. PubMed ID: 4210088
[No Abstract] [Full Text] [Related]
10. [Acquired factor deficiency: a case report and literature review].
Chen YF; Xue F; Yang YH
Zhonghua Xue Ye Xue Za Zhi; 2012 Aug; 33(8):662-3. PubMed ID: 23134865
[No Abstract] [Full Text] [Related]
11. The role of factor XIII in fibroblast proliferation.
Ueyama M; Urayama T
Jpn J Exp Med; 1978 Apr; 48(2):135-42. PubMed ID: 568677
[TBL] [Abstract][Full Text] [Related]
12. [Detection of factor XIII deficiency in acute leukemia with resonance thrombography].
Anders O; Görss EW; Ernst B; Konrad H
Folia Haematol Int Mag Klin Morphol Blutforsch; 1987; 114(5):670-9. PubMed ID: 2448208
[TBL] [Abstract][Full Text] [Related]
13. Generation and mechanism of action of a potent inhibitor of factor XIII function.
Reed GL; Lukacova D
Thromb Haemost; 1995 Aug; 74(2):680-5. PubMed ID: 8585006
[TBL] [Abstract][Full Text] [Related]
14. The effect of plasmacytomas on serum immunoglobulin levels of BALB/c mice.
Fenton MR; Havas HF
J Immunol; 1975 Feb; 114(2 pt 2):793-801. PubMed ID: 1089719
[TBL] [Abstract][Full Text] [Related]
15. Electroimmunoassay of plasma subunits-a and -s in a case of congenital fibrin stabilizing factor deficiency.
Barbui T; Cartei G; Chisesi T; Dini E
Thromb Diath Haemorrh; 1974 Sep; 32(1):124-31. PubMed ID: 4454035
[TBL] [Abstract][Full Text] [Related]
16. Male-specific cardiac pathologies in mice lacking either the A or B subunit of factor XIII.
Souri M; Koseki-Kuno S; Takeda N; Yamakawa M; Takeishi Y; Degen JL; Ichinose A
Thromb Haemost; 2008 Feb; 99(2):401-8. PubMed ID: 18278192
[TBL] [Abstract][Full Text] [Related]
17. [Factor XIII deficiency in adults with acute leukemia: results of a substitution therapy with factor XIII (author's transl)].
Havemann K; Egbring R; Gropp C; Schmidt M; Sodomann CP
Klin Wochenschr; 1977 Aug; 55(16):801-9. PubMed ID: 269298
[TBL] [Abstract][Full Text] [Related]
18. Release of immunosuppressive factor(s) by MOPC-315 murine plasmacytoma cells: a possible mechanism of defence.
Bomstein Y; Ophir R; Harshemes H; Ben-Efraim S
Anticancer Res; 1993; 13(6A):2125-9. PubMed ID: 8297124
[TBL] [Abstract][Full Text] [Related]
19. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. II. Enhancement of in vitro cell-mediated cytotoxicity by combined chemotherapy-immunotherapy.
Adler A; Keisari Y; Ofir R
J Natl Cancer Inst; 1985 Feb; 74(2):429-36. PubMed ID: 3856051
[TBL] [Abstract][Full Text] [Related]
20. Immunological studies of coagulation factor XIII.
Israels ED; Paraskevas F; Israels LG
J Clin Invest; 1973 Oct; 52(10):2398-403. PubMed ID: 4199604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
